BioCentury
ARTICLE | Clinical News

SNS01-T: Completed Phase Ib/IIa enrollment

September 15, 2014 7:00 AM UTC

Sevion (formerly Senesco Therapeutics Inc.) completed enrollment in an open-label, dose-escalation, U.S. Phase Ib/IIa trial evaluating 0.0125, 0.05, 0.2 and 0.375 mg/kg IV SNS01-T twice weekly for 6 weeks in about 15 patients with relapsed or refractory MM, DLBCL or MCL. The company said there were 2 dose-limiting toxicities (DLT) in the 8-patient cohort receiving 0.375 mg/kg SNS01-T. ...